Evidence map›Paper›PMID 36002891›Full record

ArticleAlzheimer's research & therapy2022

Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.

Andreas Giannisis, Asma Al-Grety, Henrik Carlsson, Kalicharan Patra, Daniel Twohig, Sigrid Botne Sando, Camilla Lauridsen, Guro Berge, Gøril Rolfseng Grøntvedt, Geir Bråthen and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Plasma biomarkers for Alzheimer's and related dementias: A review and outlook for clinical neuropsychology.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Andreas GiannisisDepartment of Biochemistry and Biophysics, Stockholm University, Svante Arrhenius Väg 16B, 106 91, Stockholm, Sweden.
Asma Al-GretyDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Henrik CarlssonDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Kalicharan PatraDepartment of Biochemistry and Biophysics, Stockholm University, Svante Arrhenius Väg 16B, 106 91, Stockholm, Sweden.
Daniel TwohigDepartment of Biochemistry and Biophysics, Stockholm University, Svante Arrhenius Väg 16B, 106 91, Stockholm, Sweden.
Sigrid Botne SandoDepartment of Neurology, University Hospital of Trondheim, Trondheim, Norway.
Camilla LauridsenDepartment of Neuromedicine and Movement Science (INB), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Guro BergeDepartment of Neuromedicine and Movement Science (INB), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Gøril Rolfseng GrøntvedtDepartment of Neurology, University Hospital of Trondheim, Trondheim, Norway.
Geir BråthenDepartment of Neurology, University Hospital of Trondheim, Trondheim, Norway.
Linda R WhiteDepartment of Neurology, University Hospital of Trondheim, Trondheim, Norway.
Kim KultimaDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Henrietta M NielsenDepartment of Biochemistry and Biophysics, Stockholm University, Svante Arrhenius Väg 16B, 106 91, Stockholm, Sweden. henrietta.nielsen@dbb.su.se.
Stockholm University · SENorwegian University of Science and Technology · NOSt Olav's University Hospital · NOUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLow levels of plasma apolipoprotein E (apoE) and presence of the APOE ε4 allele are associated with an increased risk of Alzheimer's disease (AD). Although the increased risk of AD in APOE ε4-carriers is well-established, the protein levels have received limited attention.

methodsWe here report the total plasma apoE and apoE isoform levels at baseline from a longitudinally (24 months) followed cohort including controls (n = 39), patients with stable amnestic mild cognitive impairment during 24 months follow up (MCI-MCI, n = 30), patients with amnestic MCI (aMCI) that during follow-up were clinically diagnosed with AD with dementia (ADD) (MCI-ADD, n = 28), and patients with AD with dementia (ADD) at baseline (ADD, n = 28). We furthermore assessed associations between plasma apoE levels with cerebrospinal fluid (CSF) AD biomarkers and α-synuclein, as well as both CSF and plasma neurofilament light chain (NfL), YKL-40 and kallikrein 6.

resultsIrrespective of clinical diagnosis, the highest versus the lowest apoE levels were found in APOE ε2/ε3 versus APOE ε4/ε4 subjects, with the most prominent differences exhibited in females. Total plasma apoE levels were 32% and 21% higher in the controls versus MCI-ADD and ADD patients, respectively. Interestingly, MCI-ADD patients exhibited a 30% reduction in plasma apoE compared to MCI-MCI patients. This decrease appeared to be associated with brain amyloid-β (Aβ

conclusionsOur results demonstrate important associations between low plasma apoE levels, Aβ pathology, and progression from aMCI to a clinical ADD diagnosis.

Indexed as

Alzheimer DiseaseApolipoproteins ECognitive Dysfunctionalpha-SynucleinAmyloid beta-PeptidesApolipoprotein E3Apolipoprotein E4BiomarkersFemaleHumansKallikreinsPeptide Fragmentstau Proteinsalpha-SynucleinAmyloid beta-PeptidesApolipoprotein E3Apolipoprotein E4Apolipoproteins EBiomarkersKallikreinsPeptide Fragmentstau ProteinsAlzheimer’s diseaseAPOE ε4Apolipoprotein EMass spectrometryPlasma

Identifiers

PMID36002891
PMCPMC9400269
OpenAlexW4293103435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.